Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor ( ) associated with favourable survival

• Published in: British journal of cancer Vol. 100; no. 5; pp. 732 - 738
• Main Authors: Kim, J-S, Kim, M-A, Kim, T M, Lee, S-H, Kim, D-W, Im, S-A, Kim, T-Y, Kim, W H, Yang, H-K, Heo, D S, Bang, Y-J, Lee, K-U, Choe, K-J, Kim, N K
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.03.2009; Nature Publishing Group
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy, Adjuvant; Cisplatin - administration & dosage; Drug Resistance; Epidemiology; Female; Fluorouracil - administration & dosage; Gastrectomy; Gastroenterology. Liver. Pancreas. Abdomen; Gene Expression Regulation, Neoplastic; Humans; Male; Medical sciences; Middle Aged; Molecular Medicine; Neoplasm Staging; Oncology; Receptor, Epidermal Growth Factor - genetics; Stomach Neoplasms - genetics; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Stomach Neoplasms - therapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Survival Analysis; Translational Therapeutics; Treatment Outcome; Tumors; Young Adult; adjuvant chemotherapy; excision repair cross-complementing gene 1; gastric cancer; thymidine phosphorylase; epidermal growth factor receptor; pharmacogenetics; Antineoplastic agent; Prognosis; Angiogenic factor; Glycosyltransferases; Adjuvant treatment; Biological marker; Stomach cancer; Epidermal growth factor receptor; Repair gene; Cancerology; Surgery; Genetics; Advanced stage; Thymidine phosphorylase; Gastric disease; Platinum II Complexes; Fluorouracil; Human; Drug combination; Pharmacogenetics; Enzyme; Fluoropyrimidine derivatives; Transferases; Enzyme inhibitor; Malignant tumor; Thymidylate synthase; Survival; Cisplatin; Alkylating agent; Chemotherapy; Treatment; Antimetabolic; Methyltransferases; Pyrimidine derivatives; Digestive diseases; excision repair cross-complementing gene I; Combined treatment; Locally advanced stage; Pentosyltransferases; Cancer
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6604936

The aim of this study was to analyse the impact of epidermal growth factor receptor ( EGFR ), thymidylate synthase ( TS ), dihydropyrimidine dehydrogenase ( DPD ), thymidine phosphorylase ( TP ), aurora kinase (ARK) A/B, and excision repair cross-complementing gene 1 ( ERCC1 ) on the efficacy of adjuvant chemotherapy with 5-fluorouracil and cisplatin (FP) after curative gastric resection. Normal and cancer tissue were separately obtained from gastrectomy samples of 153 patients with AJCC stage III–IV (M0) who subsequently treated with adjuvant FP chemotherapy. TS , DPD , TP , ERCC1 , and ARK proteins were measured by immunohistochemistry (IHC). EGFR expression was investigated using a standardized IHC with the EGFR PharmDx assay. Amplification of EGFR gene was analysed using fluorescent in situ hybridisation (FISH). In multivariate analysis, stage, ratio of positive to removed lymph nodes, and EGFR expression were significant prognostic factors for overall survival. Patients with higher EGFR expression had better overall survival than those with lower expression (relative risk: 0.475 (95% confidence interval, 0.282–0.791, P =0.005). Low EGFR expression might be a predictive marker for relapse in curative resected stage III–IV (M0) gastric cancer patients who received adjuvant FP chemotherapy.